MedicinePOM

Rucaparib

A PARP-inhibitor cancer tablet for certain BRCA-mutated ovarian and prostate cancers.

Clinical information

Common uses

maintenance of BRCA-mutated recurrent ovarian cancer
BRCA-mutated metastatic castration-resistant prostate cancer

Common side effects

feeling sick
tiredness or weakness
anaemia
raised liver enzymes
loss of appetite

Cautions

rare risk of blood cancers (MDS/AML) — blood counts monitored monthly
can harm an unborn baby — use effective contraception
skin may become sensitive to sunlight

Pregnancy: avoid — can harm an unborn baby

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, rucaparib (Rubraca) label, setid 0295d202-1cfe-7659-e063-6294a90a476e (accessed 2026-08-16)

Approved brands & formulations3

Brand name	Dosage form	Strength	Importer	Category
Rucaparib	Tablet	300mg	—	POM
Rucaparib	Tablet	200mg	—	POM
Rucaparib	Tablet	250mg	—	POM